Contineum Therapeutics (CTNM) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

CTNM Contineum Therapeutics

Watchlist

21.000
-0.060-0.28%

Close Jul 11 16:00 ET

540.19MMarket Cap-162790P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
ReutersJun 24 16:05 ET
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
BusinesswireJun 4 16:05 ET
Express News | Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
ReutersJun 3 16:05 ET
Contineum Therapeutics Sets Executive Severance Plan
TipRanksMay 31 18:00 ET
Stifel Nicolaus Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)
TipRanksMay 20 22:05 ET
Express News | Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
ReutersMay 20 16:05 ET

Comments

Pinchie McPincher

Apr 19 03:23

$Contineum Therapeutics(CTNM.US)$what am i missing?

Jaguar8

Apr 4 22:56

$Contineum Therapeutics(CTNM.US)$
NEWS
Contineum Therapeutics, Inc. announces pricing of IPO, offering 6,875,000 shares of Class A common stock at $16.00 per share, expecting gross proceeds of $110.0 million. Shares to trade on Nasdaq under symbol 'CTNM'.